Actuate Therapeutics Inc
NASDAQ:ACTUBiotechnology
+$0.06 today
- Market cap
- $50.01M
- Beta
- 0.53
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.92
Volume 0.03M
Average 0.16M
ACTU Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Actuate Therapeutics IncNASDAQ: ACTU
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q1 FY2026 net debt was -$7.73M, compared with -$3.89M a year earlier.
Context
- Net debt amounted to 86.7% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Net debt grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net debt keeps falling in the next quarterly balance sheet after a -98.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (12.75M) USD
- Year-over-year change
- -47.6%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (12.75M) | -47.6% |
| FY2024 | 2024-12-31 | (8.64M) | -192.1% |
| FY2023 | 2023-12-31 | (2.96M) | +85.2% |
| FY2022 | 2022-12-31 | (20.04M) | — |
Net Debt vs competitors
How ACTU compares with its peers on the latest reported figures
- Peers report in different currencies, so net debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -98.7% is the 7th highest of 9, against a peer median of +2.1%.
- Net debt amounts to 86.7% of total assets for ACTU, versus a peer median of 25.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $50.67M USD | +65.0% | — | 43.1% | |
| Mar 2026 | $47.64M USD | +81.1% | -6.8% | 12.8% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | -$608K USD | +95.2% | — | 2.7% |
ACTUActuate Therapeutics Inc | Mar 2026 | -$7.73M USD | -98.7% | — | 86.7% |
| Mar 2026 | -$25.59M USD | -0.9% | — | 16.4% | |
| Mar 2026 | -$42.41M USD | -1479.3% | — | 17.7% | |
| Mar 2026 | -$53.66M USD | -19.4% | — | 90.9% | |
| Mar 2026 | -CHF 75.2M CHF | +5.1% | — | 86.0% | |
| Mar 2026 | -$166.93M USD | -766.5% | — | 32.9% | |
| Peer median (excluding ACTU) | — | +2.1% | -6.8% | 25.3% | |
Competitors are the stored peer set for ACTU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Actuate Therapeutics Inc
NASDAQ:ACTU
Intrinsic Alpha fair value
Locked
Current Price
$2.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.